|
시장보고서
상품코드
2035706
비소세포 폐암(NSCLC) 시장 규모, 점유율 및 성장 분석 : 치료법별, 암 유형별, 바이오마커별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Non-Small Cell Lung Cancer Market Size, Share, and Growth Analysis, By Therapy Type, By Cancer Type, By Biomarker Type, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 비소세포 폐암 시장 규모는 2024년에 306억 8,000만 달러로 평가되었고, 2025년 349억 4,000만 달러에서 2033년까지 989억 8,000만 달러로 확대되어 예측 기간(2026-2033년)에 CAGR 13.9%를 보일 전망입니다.
비소세포 폐암(NSCLC) 시장은 1차 치료에서 면역관문억제제(ICI)의 도입에 힘입어 크게 성장하고 있습니다. 비소세포 폐암은 전 세계 폐암 환자의 80-85%를 차지하며, 주요 시장 기업들은 혁신적인 치료법 개발 및 기존 치료의 효과 향상에 집중하고 있습니다. 또한, 이 질환이 전 세계적으로 가장 흔하고 치사율이 높은 암 중 하나라는 사실도 시장 확대를 더욱 부추기고 있습니다. 비소세포 폐암 진단율 증가와 더불어 선진국과 신흥 시장에서 일반 대중의 인식이 높아진 것이 이러한 성장의 열쇠가 되고 있습니다. 또한, 주요 기업들의 비소세포 폐암 치료제의 연구 파이프라인 임베디드과 연구개발(R&&D)에 대한 투자 확대가 세계 시장 성장을 견인하고 있습니다.
세계 비소세포 폐암 시장 성장 요인
세계 비소세포 폐암(NSCLC) 시장의 성장에 기여하는 몇 가지 요인이 있습니다. 폐암의 유병률은 증가 추세에 있으며, 주요 요인으로는 흡연 습관, 석면, 카드뮴, 라돈 등의 환경오염물질, 그리고 HIV 감염 증가를 꼽을 수 있습니다. 또한, 인구의 지속적인 증가도 폐암 발병 위험에 처한 사람들의 수에 큰 기여를 하고 있습니다. 이러한 상호 연관된 요소들은 비소세포 폐암 시장에서 혁신적인 치료법과 치료법에 대한 수요를 증가시키고 있으며, 이 심각한 공중보건 문제를 해결하기 위한 헬스케어 솔루션의 발전이 시급하다는 것을 강조하고 있습니다.
세계 비소세포 폐암 시장 성장 억제요인
세계 비소세포 폐암 시장이 직면한 큰 과제 중 하나는 높은 치료비입니다. 화학요법, 수술, 표적치료, 방사선치료, 면역요법 등 다양한 치료방법은 효과적이지만 경제적 부담이 큽니다. 이러한 고가의 치료비는 환자가 필요한 치료를 받는 것을 방해할 수 있으며, 전체 시장의 성장을 제한할 수 있습니다. 그 결과, 이러한 치료의 고비용성은 비소세포 폐암 시장 확대에 큰 제약이 되고 있으며, 환자 접근성을 개선하고 시장 잠재력을 높이기 위해 보다 합리적인 가격의 솔루션이 필요함을 강조하고 있습니다.
세계 비소세포 폐암 시장 동향
세계 비소세포 폐암(NSCLC) 시장은 선진국과 신흥국 모두에서 진단 건수 증가와 인식 제고에 힘입어 괄목할 만한 성장을 보이고 있습니다. 이러한 추세는 주요 제약사들이 연구개발에 많은 투자를 하고 있으며, 이는 혁신적인 치료법의 도입을 촉진하고 있습니다. 또한, 첨단 치료법 및 맞춤형 의료가 치료 프로토콜에 통합되면서 환자의 치료 결과가 개선되고 시장 수요가 증가하고 있습니다. 이해관계자들이 협력하여 새로운 치료법에 대한 접근성을 개선하는 가운데 비소세포 폐암 시장은 전 세계적으로 이 흔한 암에 대처하기 위한 광범위한 노력을 반영하여 강력한 성장이 예상되고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 비소세포 폐암 시장 규모 : 치료법별
세계의 비소세포 폐암 시장 규모 : 암 유형별
세계의 비소세포 폐암 시장 규모 : 바이오마커 유형별
세계의 비소세포 폐암 시장 규모 : 유통 채널별
세계의 비소세포 폐암 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSHGlobal Non-Small Cell Lung Cancer Market size was valued at USD 30.68 Billion in 2024 and is poised to grow from USD 34.94 Billion in 2025 to USD 98.98 Billion by 2033, growing at a CAGR of 13.9% during the forecast period (2026-2033).
The market for non-small cell lung cancer (NSCLC) is experiencing significant growth, driven primarily by the introduction of immune checkpoint inhibitors (ICIs) in first-line treatment. NSCLC accounts for 80-85% of global lung cancer cases, prompting major market players to focus on developing innovative therapies and enhancing the efficacy of existing treatments. The disease's status as one of the most common and deadly cancers worldwide further fuels market expansion. Rising rates of NSCLC diagnoses, coupled with heightened public awareness in both developed and emerging markets, are pivotal to this growth. Additionally, the inclusion of NSCLC therapies in the research pipelines of leading companies, along with increased investment in R&D initiatives, is propelling the global market forward.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Small Cell Lung Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Non-Small Cell Lung Cancer Market Segments Analysis
Global Non-Small Cell Lung Cancer Market is segmented by Therapy Type, Cancer Type, Biomarker Type, Distribution Channel and region. Based on Therapy Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Others. Based on Cancer Type, the market is segmented into Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma and Others. Based on Biomarker Type, the market is segmented into EGFR Mutation, ALK Rearrangement, ROS1 Mutation, BRAF Mutation, PD-L1 Expression and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Non-Small Cell Lung Cancer Market
Several factors are contributing to the expansion of the global non-small cell lung cancer (NSCLC) market. The prevalence of lung cancer is increasing, largely attributed to smoking habits, environmental pollutants such as asbestos, cadmium, and radon, as well as the growing incidence of HIV infections. Additionally, the continuous rise in population contributes significantly to the number of individuals at risk for developing lung cancer. These interconnected elements are creating a heightened demand for innovative treatments and therapies in the NSCLC market, emphasizing an urgent need for advancements in healthcare solutions to tackle this serious public health issue.
Restraints in the Global Non-Small Cell Lung Cancer Market
One of the significant challenges facing the global non-small cell lung cancer market is the high cost of treatments. Various therapeutic options, including chemotherapy, surgery, targeted therapies, radiation therapy, and immunotherapy, although effective, come with substantial financial burdens. This elevated price point can deter patients from accessing necessary care and may limit overall market growth. Consequently, the expensive nature of these treatments poses a considerable restraint to the expansion of the non-small cell lung cancer market, highlighting the need for more affordable solutions to improve patient access and enhance market potential.
Market Trends of the Global Non-Small Cell Lung Cancer Market
The Global Non-Small Cell Lung Cancer (NSCLC) market is witnessing significant growth driven by rising diagnoses and heightened awareness across both developed and emerging economies. This trend is further supported by leading pharmaceutical companies investing heavily in research and development, which is catalyzing the introduction of innovative treatment options. Additionally, the integration of advanced therapeutic modalities and personalized medicine into treatment protocols is enhancing patient outcomes and fueling market demand. As stakeholders collaborate to improve access to novel therapies, the NSCLC market is positioned for robust expansion, reflecting a broader commitment to tackling this prevalent cancer on a global scale.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Technology Analysis
- Pipeline Analysis
- Disease Epidemiology
- Patent Analysis
Global Non-Small Cell Lung Cancer Market Size by Therapy Type & CAGR (2026-2033)
- Market Overview
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy
- Others
Global Non-Small Cell Lung Cancer Market Size by Cancer Type & CAGR (2026-2033)
- Market Overview
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Others
Global Non-Small Cell Lung Cancer Market Size by Biomarker Type & CAGR (2026-2033)
- Market Overview
- EGFR Mutation
- ALK Rearrangement
- ROS1 Mutation
- BRAF Mutation
- PD-L1 Expression
- Others
Global Non-Small Cell Lung Cancer Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Global Non-Small Cell Lung Cancer Market Size & CAGR (2026-2033)
- North America (Therapy Type, Cancer Type, Biomarker Type, Distribution Channel)
- US
- Canada
- Europe (Therapy Type, Cancer Type, Biomarker Type, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Therapy Type, Cancer Type, Biomarker Type, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Therapy Type, Cancer Type, Biomarker Type, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Therapy Type, Cancer Type, Biomarker Type, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Daiichi Sankyo Company, Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BeiGene, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exelixis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
